Post-earnings recap
Reported
Wed, Mar 30, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Crinetics Pharmaceuticals reported a wider-than-expected loss per share, which contributed to the stock's decline of 3.41% following the earnings announcement. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term prospects. Management's cautious tone suggests that challenges remain, which could impact future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.68 | N/A | -20.35% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced during the quarter. They emphasized the importance of innovation and product pipeline but did not provide specific guidance.
Management expressed concerns about ongoing challenges in the market.
They highlighted the need for continued focus on product development.
No specific guidance was provided for future quarters.